EVARMED

EVARMED is developing an injectable viscosupplement, EVARVISC™, designed to address symptoms of OSTEOARTHRITIS in animals. EVARVISC™ offers prolonged efficacy, requiring only one annual injection. This significantly reduces the need for multiple treatments compared to conventional hyaluronic acid-based products, thereby minimizing unnecessary stress on animals. Furthermore, EVARVISC™ represents the most economically viable option relative to standard offerings in the market. We work hard to bring this product to the market in 2027.